AstraZeneca’s “Smart Risks” Include Sharing FibroGen’s Anemia Compound With Astellas
This article was originally published in The Pink Sheet Daily
Executive Summary
The British pharma continues to build its cardiovascular and metabolic pipeline to slow its dive off the patent cliff; in FibroGen’s FG-4592, it sees a potential strong seller in regions where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.